Abstract
Objective: Although allergic conjunctivitis seldom causes visual impairment, it holds significance due to its frequency and severity. This study was carried out to compare the safety and efficacy of Alcaftadine 0.25% and Olapatadine 0.2% ophthalmic solutions in treating the symptoms and signs of allergic conjunctivitis as there is not much literature comparing these two drugs directly. Materials and methods: This is a prospective, observer masked study of 80 patients with allergic conjunctivitis assigned to two groups-Group I: 40 patients received Alcaftadine 0.25% and Group II:40 patients received Olapatadine 0.2% ophthalmic solution and relief of symptoms were noted and assessed with a follow at 1 week and 1 month. Results: Eyes treated with Alcaftadine 0.25% had significantly low mean itch score of 0.6 compared to Olapatadine 0.2% ophthalmic solution which was 1. Eyes treated with both Alcaftadine 0.25% and Olapatadine 0.2% ophthalmic solutions reduced lid swelling, redness and discharge; safe and no serious adverse effects were encountered. Conclusion: BothAlcaftadine 0.25% and Olapatadine 0.2% ophthalmic solutions used in the study are safe and effective in treating the symptoms and signs of Allergic conjunctivitis. However, Alcaftadine 0.25% ophthalmic solution is comparatively more efficacious.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Membrane Science and Technology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
